-transparent.png){kind=logo}
Haloperidol- and sulpiride-displaceable [3H]spiroperidol binding and the dopamine-inhibited adenylate cyclase were measured in rats chronically exposed to lead acetate. Haloperidol-displaceable [3H]spiroperidol binding was unmodified while sulpiride-displaceable binding was increased in striatum and decreased in nucleus accumbens. In addition, the decrease of sulpiride-displaceable binding in nucleus accumbens was paralleled by a reduced ability of bromocriptine to inhibit cAMP formation in presence of the D1 receptor antagonist SCH 23390. The results support the concept that in vivo lead treatment affects dopaminergic receptors and that the binding sites labelled by [3H]spiroperidol displaced by haloperidol may be different from those which recognize sulpiride.
S Govoni, and
L Lucchi, and
C Missale, and
M Memo, and
P F Spano, and
M Trabucchi
January 1978,
Gerontology,
S Govoni, and
L Lucchi, and
C Missale, and
M Memo, and
P F Spano, and
M Trabucchi
October 1984,
Toxicology,
S Govoni, and
L Lucchi, and
C Missale, and
M Memo, and
P F Spano, and
M Trabucchi
June 2007,
Neuroscience letters,
S Govoni, and
L Lucchi, and
C Missale, and
M Memo, and
P F Spano, and
M Trabucchi
December 1999,
Pharmacology, biochemistry, and behavior,
S Govoni, and
L Lucchi, and
C Missale, and
M Memo, and
P F Spano, and
M Trabucchi
April 2014,
Neuropharmacology,
S Govoni, and
L Lucchi, and
C Missale, and
M Memo, and
P F Spano, and
M Trabucchi
December 2005,
Neurochemical research,
S Govoni, and
L Lucchi, and
C Missale, and
M Memo, and
P F Spano, and
M Trabucchi
January 2000,
Annual review of neuroscience,
S Govoni, and
L Lucchi, and
C Missale, and
M Memo, and
P F Spano, and
M Trabucchi
December 1989,
Brain research,
S Govoni, and
L Lucchi, and
C Missale, and
M Memo, and
P F Spano, and
M Trabucchi
February 1982,
Brain research,
S Govoni, and
L Lucchi, and
C Missale, and
M Memo, and
P F Spano, and
M Trabucchi
March 2006,
Neuropharmacology,
